Feasibility of Individualized Therapy for Recurrent Glioblastoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 19, 2018

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2026

Conditions
Recurrent Glioblastoma
Interventions
DRUG

Individualized therapy

"1. For a given proposed individualized combination of drugs the first priority to establish doses will be to identify the same combination of drugs in a peer-reviewed journal article or presented as a reviewed abstract.~2. When a proposed individualized combination of drugs has not previously been reported, the process to establish doses will be to then identify individual members of the proposed combination that have been used in combination with other cytotoxic agents similar to those being considered for combination therapy.~3. When a proposed individualized combination of drugs has no available combination data, dosing guidelines will start with the FDA-approved package insert recommended dose."

Trial Locations (1)

94143

University of California San Francisco, San Francisco

All Listed Sponsors
lead

Jennifer Clarke

OTHER